Prospective Partners

PDS welcomes additional partners to develop the novel Versamune®-based immunotherapies, as well as human and veterinary preventive vaccines.

Parties interested in collaborating with PDS or in licensing the Versamune® vector technology for use in vaccines and at: immunotherapies should contact PDS Biotechnology Corporation.

Michael King

Email: mking@pdsbiotech.com
Tel: 609-610-4604

For Scientific Inquiries, please contact:

Dr. Greg Conn

Email: gconn@pdsbiotech.com
Tel: 732-640-0045